Annals of Nuclear Medicine

, Volume 22, Issue 4, pp 301–307 | Cite as

Evaluation of brain and whole-body pharmacokinetics of 11C-labeled diphenylhydantoin in rats by means of planar positron imaging system

  • Yukinori Hasegawa
  • Yasukazu Kanai
  • Shinji Hasegawa
  • Takashi Okamoto
  • Tamiko Matsui
  • Eku Shimosegawa
  • Yoshihisa Kurachi
  • Jun HatazawaEmail author
Original Article



A planar positron imaging system (PPIS) enables whole-body dynamic imaging of radiopharmaceuticals labeled with positron-emitting nuclides. We evaluated the difference in the brain and whole-body pharmacokinetics of 11C-diphenylhydantoin (11C-DPH) between intravenous and duodenal administration in rats.


Male Wistar rats (8 weeks old, mean body weight 250 g) were examined under anesthesia. A tracer amount of 11C-DPH (2 μg or less; about 5 MBq) was injected into the tail vein (n = 3) or duodenum (n = 3). Immediately following the administration, PPIS scans were obtained for 20 min. Regions of interest (ROIs) were set on the brain, heart, liver, intestinal field, and urinary bladder, identified on the integrated images. The relative uptake value (RUV, %) was calculated as the regional count divided by the whole-body count multiplied by 100. Sequential changes in the RUV for each ROI were analyzed for the brain and other organs.


Following intravenous injection of 11C-DPH, the RUV in the brain was 1.59 ± 0.07%, 1.53 ± 0.09%, 1.40 ± 0.09%, and 1.38 ± 0.08% at 5 min, 10 min, 15 min, and 20 min after the injection, respectively. After duodenal administration, the corresponding values were 0.54 ± 0.16%, 1.01 ± 0.12%, 1.43 ± 0.24%, and 1.52 ± 0.06%, respectively. The 11C-DPH distribution was significantly lower at 5 min and 10 min following duodenal administration than after intravenous injection (P < 0.01). Radioactivity in the urinary bladder was identified by 20 min after both intravenous injection and duodenal administration.


The present study demonstrated a difference in the brain distribution of 11C-DPH between intravenous and duodenal administration in rats. Use of the PPIS is feasible for the evaluation of the pharmacokinetics in both the target organ and the whole body in small animals.


PPIS 11C-DPH Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Uchida H, Okamoto T, Ohmura T, Shimizu K, Satoh N, Koike T, et al. A compact planar positron imaging system. Nucl Instrum Methods Phys Res A 2004;A516:564–574.CrossRefGoogle Scholar
  2. 2.
    Tsukada H, Sato K, Fukumoto D, Nishiyama S, Harada N. Evaluation of d-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with l-and d-11C-methionine. J Nucl Med 2006;47:679–688.PubMedGoogle Scholar
  3. 3.
    Alvin JD, Bush MT. Diphenylhydantoin and other hydantoins. In: Vida JA, editor. Anticonvulsivants. New York: Academic Press; 1977. p. 116.Google Scholar
  4. 4.
    Noach EL, Woodbury DM, Goodman LS. Studies on the absorption, distribution, fate and excretion of 4-C14-labeled diphenyhydantoin, J Pharmacol Exp Therap 1958;122:301–314.Google Scholar
  5. 5.
    Noach EL, Rees HV. Intestinal distribution of intravenously administered diphyenythydontoin in the rat. Arch Int Pharmacodyn 1964;150:52–61.PubMedGoogle Scholar
  6. 6.
    Stavchansky SA, Tibury RS, McDonald JM, Ting CT, Kostenbauder HB. In vivo distribution of carbon-11 phenytoin and its major metabolite, and their use in scintigraphic imaging. J Nucl Med 1978;19:936–941.PubMedGoogle Scholar
  7. 7.
    Baron JC, Roeda D, Murani C, Crouzel C, Chodkiewicz JP, Comar D. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology 1983;33:580–585.PubMedGoogle Scholar
  8. 8.
    Roeda D, Crouzel C, Van Zanten B. The production of 11C-phosgene without added carrier. Radiochem Radioanal Lett 1978;33:175–178.Google Scholar
  9. 9.
    Roeda D, Westera G. The synthesis of some 11C-labelled anti-epileptic drugs with potential utility as radiopharmaceuticals: hydantoins and barbiturate. Int J Appl Radiat Isot 1981;32:843–845.PubMedCrossRefGoogle Scholar
  10. 10.
    Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005;18:1868–1875.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamazaki H, Komatsu T, Takemoto K, Saeki M, Minami Y, Kawaguchi Y, et al. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab Dispos 2001;29:427–434.PubMedGoogle Scholar
  12. 12.
    Firemark H, Barlow CF, Roth LJ. The entry, accumulation and binding of diphenylhydantoin-2-C14 in brain. Int J Neuropharmacol 1963;2:25–38.CrossRefGoogle Scholar
  13. 13.
    Inaba T, Umeda T. Biliary excretion of diphenylhydantoin in the rat: time-course studies. Drug Metab Dispos 1975;3:69–73.PubMedGoogle Scholar
  14. 14.
    A Monaem, EL-Hawari, Gabriel LPLAA. Role of the enterohepatic circulation in the elimination of phenytoin in the rat. Drug Metab Dispos 1978;6:59–69.Google Scholar
  15. 15.
    Suzuki T, Saito Y, Nishihara K. Kinetics of diphenylhydantoin disposition in man. Chem Pharm Bull 1970;18:405–411.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2008

Authors and Affiliations

  • Yukinori Hasegawa
    • 1
  • Yasukazu Kanai
    • 1
  • Shinji Hasegawa
    • 1
  • Takashi Okamoto
    • 2
  • Tamiko Matsui
    • 3
  • Eku Shimosegawa
    • 1
  • Yoshihisa Kurachi
    • 4
  • Jun Hatazawa
    • 1
    Email author
  1. 1.Department of Nuclear Medicine and Tracer KineticsOsaka University Graduate School of MedicineOsakaJapan
  2. 2.Hamamatsu Photonics K.K.HamamatsuJapan
  3. 3.Nihon Medi-Physics Co. Ltd.NishinomiyaJapan
  4. 4.Department of PharmacologyOsaka University Graduate School of MedicineOsakaJapan

Personalised recommendations